Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Company Overview - Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers [3] - The company was co-founded by pioneers in precision oncology and RAS targeting, aiming to create novel therapies and combination regimens to comprehensively shut down the RAS/MAPK pathway [3] - Erasca has one of the deepest RAS/MAPK pathway-focused pipelines in the industry, supported by a scientific advisory board of leading experts [3] Recent Events - Erasca announced its participation in the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 9:30 am Eastern Time, where management will engage in a fireside chat and one-on-one investor meetings [1] - A live audio webcast of the event will be available on Erasca's website, with an archived replay accessible for 30 days post-event [2]